Talquetamab is a bispecific T-cell engager targeting GPRC5D and CD3. It received accelerated approval from the U.S. FDA in 2023 for the treatment of relapsed or refractory multiple myeloma.
Indications for Talquetamab
Primary Indication
The indication of talquetamab is specifically for relapsed or refractory multiple myeloma.
Target Patient Population
It is indicated for adult patients who have previously received at least 4 lines of systemic therapy, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies.
Specifications and Properties of Talquetamab
Specification of 3 mg/1.5 mL (2 mg/mL)
Appearance: Clear to pale yellow solution, with a red flip-top cap.
Excipients: Contains disodium edetate, glacial acetic acid, polysorbate 20, sodium acetate, sucrose, and water for injection; pH is approximately 5.2.
Specification of 40 mg/mL
Appearance: Clear to pale yellow solution, with a blue flip-top cap.
Excipients: Same as the 3 mg/1.5 mL specification, but with a higher concentration.
Property Verification
Before use, check that the solution is clear and free of particles. If turbidity, discoloration, or foreign matter is present, do not use the product.
Storage Methods for Talquetamab
Unopened Vials
Store in the original packaging in a refrigerator at 2°C–8°C, protected from light. Freezing or shaking is prohibited.
When temporarily removed from refrigeration, it can be stored at 15°C–30°C for a maximum of 24 hours (must be protected from light).
Reconstituted Solution
It is best to use immediately after reconstitution. Alternatively, it can be stored under refrigeration (2°C–8°C) for 24 hours, followed by storage at room temperature (15°C–30°C) for another 24 hours; the total storage time must not exceed 48 hours.
If stored under refrigeration, the solution must be brought to room temperature before injection.
Disposal: Unused medicinal solution or expired drugs must be disposed of through professional medical waste disposal channels.
